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YKL-40 is a secreted glycoprotein, which is a shared biomarker of chronic inflammation 
and oncogenic transformation. Indeed, YKL-40 expression is up-regulated in many diseases 
including multiple sclerosis, Alzheimer disease, viral encephalitis, HIV-associated 
dementia, brain infarction, and traumatic brain injury. YKL-40 is also expressed by several 
solid tumors, such as osteosarcoma, ovarian carcinoma and glioblastoma multiforme 
(GBM). It promotes the migration and invasion of astrocytes as well as GBM cells. Serum 
YKL-40 levels have been shown to directly correlate with tumor grade and potentially 
tumor burden in GBM. In contrast to the numerous reports documenting elevated  
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expression of YKL-40, relatively little is known about inflammatory mediators and specific 
molecular mechanisms that control its expression. For my PhD project, I decided to 
elucidate the mechanism regulating YKL-40 expression in inflammation and to understand 
how YKL-40 mediates the migration and invasion of GBM cells in vivo. As per my first 
project, I found that YKL-40 expression is up-regulated in many inflammatory models such  
as irritant induced inflammation (turpentine), EAE (experimental autoimmune 
encephalomyelitis), irradiation induced brain inflammation and in the HIV-TAT 
overexpression model. YKL-40 expression is also up regulated in oligodendroglioma 
patient samples. We show that YKL-40 expression is activated by major pro-inflammatory 
cytokines including IL-1, IL-6, and OSM in astrocytes, and that the activation of YKL-40 
expression by cytokines depends on the STAT and NF-κB regulatory elements located 
within the YKL-40 promoter. Additionally, we discovered that STAT3 is a major regulator  
of YKL-40 expression in response to the IL-6 family cytokines, including OSM. Indeed, 
both depletion of STAT3 expression or overexpression of dominant-negative STAT3 
abolishes activation of YKL-40 expression. In contrast, although IL-1 activates NF-κB 
(p65/p50) in astrocytes, IL-1-induced YKL-40 expression is p65/p50 independent, and 
instead regulated by the RelB/p50 complexes. Interestingly, OSM promotes formation of 
p50/RelB complexes. In conclusion, we found that YKL-40 is up regulated by major pro-
inflammatory cytokines during inflammation associated with various disease models. Thus, 
we uncovered the regulatory mechanism that governs the expression of YKL-40 during 
sterile inflammation. 
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Next, I studied the role of YKL-40 in GBM in vivo. The major obstacle for 
treatment of GBM is the unique ability of GBM cells to diffusely infiltrate healthy brain  
tissue. GBM tumors express high levels of YKL-40, and we showed that administration of  
YKL-40 increases migration and invasion of U1242 cells in vitro. We used the U1242 cell 
line for our studies, due to its unique ability to form infiltrative tumors, which reflects the 
real brain pathology in GBM. Additionally, knock-down of YKL-40 suppresses the 
migration and invasion of GBM cells in vitro. To study this phenomenon in vivo, we 
utilized an inducible lentiviral vector containing shRNA to YKL-40. We generated stable 
GBM cells containing this shYKL-40 vector and used them in a mouse xenograft model for 
glioma to evaluate the effect of YKL-40 in invasion and migration of GBM cells. 
RelB expression is increased in GBM patients, and it is associated with up-regulation of a 
distinct subset of gene. Here we show that RelB expression is increased during 
inflammation in response to IL-1, where it can enhance the expression of YKL-40, which 
can modulate the inflammatory response. 
Thus, we found that YKL-40 is up regulated by major inflammatory cytokines during 
inflammation associated with various diseases. In addition, YKL-40 secreted by brain cells 
other than GBM cells may have an effect on invasion of GBM cells in vivo.
1 
 
1 
 
 
 
Chapter 1 
 Introduction 
1.1 Sterile Inflammation 
             Inflammation is putatively understood to be a response to pathogenic stimuli, which can 
result in redness, swelling, pain and increased temperature. However, sterile inflammation, 
“occurs in the absence of microbial or infectious stimuli, and instead occurs in response to 
physical, chemical or metabolic noxia”. Myocardial infarction, trauma, and ischemia, are some 
examples of diseases associated with sterile inflammation (1). Amplification of the immune 
response occurs once PAMPs (pathogen associated molecular patterns) are detected on bacterial 
surfaces and released by viruses. Pattern recognition receptors (PRPs), including toll like 
receptors (TLRs) , NOD like receptors (NLRs) and RIG-1 are expressed by innate immune cells 
and bind to PAMPs to activate the innate immune cascade to overcome intruding pathogens (2). 
In case of sterile inflammation, a similar mechanism occurs to activate the immune response due 
to stimuli called DAMPs (damage associated molecular patterns). DAMPs include DNA, RNA, 
heat shock proteins (HSP), high mobility group box-1, cholesterol crystals (3, 4), which are 
normally sequestered but are released due to cell death and damage. Similar to infectious 
inflammation, activation of immune cells by DAMPs leads to increased expression of 
inflammatory cytokines and the recruitment of immune cells. Excessive inflammation can lead to 
various pathological conditions including gout, arthritis, type 1 diabetes,  
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Alzheimer’s disease and multiple sclerosis. Multiple sclerosis is a inflammatory disease, which 
results in demyelination, oligodendrocyte cell death, and axonal degeneration. 
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Picture modified from- Sterile inflammation: sensing and reacting to damage. Grace Y. Chen1 & 
Gabriel Nuñez. Nature Reviews Immunology. December 2010. 
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Figure 1 Mechanism for Inducing Sterile Inflammation. Sterile stimuli that include damage-
associated molecular patterns (DAMPs), sterile particulates and intracellular cytokines released 
from necrotic cells can activate the host immune system to induce sterile inflammation through 
at least three pathways that are not mutually exclusive. (3) 
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1.2 Astrocytes 
Astrocytes are the most abundant cell type in the CNS, which emphasizes their ability to 
modulate a range of homeostatic and pathologic condition. The most common markers of 
astrocytes are GFAP and vimentin, which are intermediate filament proteins (5). Astrocytes are 
evolutionary conserved suggesting that their basic functions remain conserved as well. 
Astrocyte also exhibit morphological diversity as well as inherent functional specialization. They 
can be classified into five types based on their anatomical location. (1) White matter astrocytes, 
which have star like appearance due to numerous fine projections, some of which are GFAP 
positive; (2) Grey matter astrocytes, which also referred as ‘protoplasmic’, and have a less 
complex morphology, and are GFAP negative;(3) Ependymal astrocytes, which are closest to 
progenitor cells, are GFAP positive and are located in the stem cell niches; (4) Radial glia, which 
are located in the cerebral cortex, direct migration and provide a scaffold for migrating neurons 
during brain development; (5) Perivascular astrocytes, which form “vascular feet” which are 
specialized projections around the neurovasculature, and are GFAP positive as well.  
In the past, these cells were considered to be space filling cells of the CNS (central nervous 
system), and only responsible for providing support to the neighboring excitable neuron. 
Astrocytes are located in close proximity of neurons and endothelial cells of the BBB (5), where 
they form a light association. Additionally, astrocytes provide energy and substrates to neurons 
to maintain homeostatic conditions. In regions of active neurotransmission at the synapse, 
astrocytes dilate the BBB to allow the exchange of oxygen and glucose in active regions of the  
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brain. Astrocytes, during early brain development, secrete factors that are critical for active 
synapse formation and synapse elimination (6). Radial glia, during early  
brain development, act as stem cells and differentiate to neurons and oligodendrocytes (7, 8). 
Many developmentally regulated tropic and trophic factors are secreted by astrocytes which help 
and direct exons during post natal brain development. Expression of these factors is increased 
during pathological conditions of the brain associated with astrogliosis. Hence, with the 
identification of more diverse functions of astrocytes in CNS homeostasis, it can be concluded 
that astrocytes control many functions in normal as well as pathological states of the brain.  
 
1.3 Chitinase 3-like 1 (CHI3L1) or YKL-40 
YKL-40 also known as human cartilage glycoprotein-39 (HC gp-39), Chitinase 3-like protein-1 
(CHI3L1), mouse homologue breast regression protein-39 (BRP-39), is a secreted 40 kDa 
glycoprotein. In humans, the gene for YKL-40 is located on chromosome 1q31-q32. YKL-40 
belongs to glycohydrolase family, which is comprised of many bacterial and eukaryotic 
proteins having a chitinase activity (9, 10). 
The YKL-40 protein is comprised 383 amino acids and is synthesized with an 8 amino acid N-
terminal pro-peptide sequence which is cleaved before the protein is secreted. Even though it belongs 
to a family of chitinases, YKL-40 is an enzymatically inactive, due to a single amino  
acid substitution of glutamate to leucine in its core chitinase binding pocket; though it still binds to  
 
 
 
 
7 
 
 
chitin and many other carbohydrate molecules (10) 
In normal individuals, YKL-40 is secreted by neutrophils, and chondrocytes, synoviocytes, and 
smooth muscle cells (10). It is also highly up-regulated during the differentiation of  monocytes to 
macrophages, and  during smooth muscle cell differentiation (11). However, recently it has been 
regarded as a marker of chronic inflammation and transformation. YKL-40 expression has been found 
to be highly up-regulated in many pathologies associated with ongoing  inflammation, tissue 
remodeling  and  cancer  such as rheumatoid  arthritis, osteoarthritis, asthma, breast cancer, GBM, 
papillary thyroid carcinoma, extraskeletal myxoid 4chondrosarcoma, colon cancer, melanoma 
and metastatic prostate cancer. In addition, elevated levels of YKL-40 are also correlated with 
the disease severity and high mortality rates during various pathological states, including GBM. 
Recently, microarray data has indicated that, YKL-40 is one of the most up-regulated gene in 
GBM (12). 
In vitro studies have shown that the expression of YKL-40 increases upon stimulation with pro-
inflammatory cytokines in macrophages and other cell types including chondrocytes, and cancer 
cells (10) (13). In addition, YKL-40 knock-out mice showed impaired antigen induced Th2 
responses, with YKL-40 being a potent inhibitor of death-receptor induced inflammatory cell 
apoptosis. In addition, the expression levels of IL-4 and IL-13 was decreased in YKL-40 null 
animals challenged with OVA (ovalbumin) antigen compared to the sham-treated animals (14).  
Even though YKL-40 is up-regulated in many inflammation associated pathologies, regulation  
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of its expression and the functions of YKL-40 are not well defined. Analysis of the -1.3 kb 
upstream region of YKL-40 promoter revealed presence of several transcription factor 
binding sites, including AP-1, CEBP, Sp1, Sp3, NF-κB and ETS (11). Previously it has been 
shown that during monocyte to macrophage differentiation expression of YKL-40 is mainly 
controlled by the SP-1 transcription factor ( 1 1 ) .  In response to pro-inflammatory cytokines 
IL-1 and TNFα, expression of YKL-40 is regulated by p65(NF-κB) in chondrocytes (13). In 
contrast, IL-1 and TNFα represses YKL-40 expression in glioma cells (15).Therefore, cell and 
tissue specific regulation in expression of YKL-40 cannot be ruled out. In addition, the level of 
YKL-40 expression increases upon stress stimuli including, hypoxia, cell confluence, serum 
starvation, and genotoxic stress (UV irradiation) in glioma cells ( 1 6 ) . Interestingly, hypoxia 
induced expression of YKL-40 was independent of the HIF-1 transcription factor (16). 
There have been studies indicating the functions of YKL-40. It has been shown to work as a 
mitogenic factor for several cell types including skin and lung fibroblasts, chondrocytes and 
synovial cells.YKL-40, also acts as a pro-survival factor when cells are exposed to stress 
conditions (10). Moreover, primary transformed astrocytes overexpressing YKL-40 express 
genes conferring resistance to irradiation treatment (17).  
YKL-40 can also serve as chemotactic factor for HUVEC (Human umbilical vein endothelial 
cell), and as an adhesion and migration factor for vascular smooth muscle cells. Indeed, its 
overexpression significantly increases migration of transformed astrocytes (17). Thus, in  
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general, YKL-40 appears to function as a tissue remodeling, pro- survival, and pro-growth 
factor. In accordance with its prosurvival and pro-growth functions, YKL-40 has been shown to 
activate MAPK/ERK1/2(Mitogen-activated protein kinases/ Extracellular signal-regulated 
kinases) and PI3K/AKT (Phosphatidylinositol-4,5-bisphosphate 3-kinase) signaling when added 
exogenously (18, 19). Despite these findings, the precise mechanism of YKL-40 action is yet to 
be elucidated. Because YKL-40 contains a heparan binding motif it was postulated to bind 
carbohydrate moites on the surface of cells. Interestingly, it has recently been shown that YKL-
40 can bind to syndecan-1 (receptor for heparan sulfate binding protein) and that binding event 
further enhances syndecan-1 association with αѵβ3 integrin. The syndecan-integrin complex 
formation leads to the phosphorylation and activation of FAK, and subsequent activation of 
ERK1/2 and PI3K (18). Recently, it was shown that YKL-40 binds to IL-13Rα2 and stimulates 
MAPK, Akt/PKB, and Wnt//β-catenin signaling and regulates oxidant injury, apoptosis, and 
pyroptosis via IL-13Rα2 (20). In addition, YKL-40 could promote BSMC (Bronchial smooth 
muscle cells) proliferation and migration directly via a protease-activated receptor-2–dependent 
pathway (21). YKL-40 has been identified during various studies, to recognize potential markers 
and targets for a subset of CNS pathologies. YKL-40 levels are elevated in the CSF of patients 
with schizophrenia, Alzheimer’s disease, Parkinson`s disease, multiple sclerosis, RETT 
syndrome, and GBM (12, 22, 23).  
However, the regulation and role of YKL-40 in CNS cell types remains elusive. Recently, it has 
been shown that increased expression of YKL-40 is associated with the increase in CSF  
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(Cerebrospinal fluid) viral load in SIVE (Simian Immunodeficiency Virus Infection) and MS 
patients. This increased YKL-40 expression was found in association with the microglial 
nodules in SIVE (24). YKL-40 is expressed by astrocytes in vitro, and its expression is regulated 
by NFI-X3 and STAT3 (25). Even though  regulation of its expression in normal brain 
(astrocytes) has been shown by our lab, regulation of its expression during various CNS 
pathologies remains open for further analysis  
 
1.4 Glioblastoma 
Astrocytic tumors, which are widely represented by glioblastomas, are the most aggressive and 
fatal type of brain tumors (26). Four such astrocytic tumors are; (1) Pilocytic astrocytoma, grade 
I is benign and can be surgically removed, (2) whereas grade II diffuse astrocytoma, is of low 
malignancy and requires long-term clinical treatments; (3) Anaplastic astrocytoma, grade III, is 
malignant and leads to the patient’s death within a few years; (4) GBM, grade IV is highly 
malignant and causes death within months. GBM is the most common type of primary brain 
tumor, with a 5-year survival rate of less than 3%. A unique clinical problem in treating GBM is 
the extensive invasiveness of GBM cells. The mortality of patients with GBM  remains high due 
to the ineffectiveness of current therapies, which include surgery, radio, and chemotherapy. The 
high rate of tumor relapse is due to the infiltrative nature of GBM. The high rate of tumor  
relapse points to the need for more targeted therapeutic approaches. There are several molecular 
markers that help to characterize these tumors (27), such as mutations in the p53 and  
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retinoblastoma (RB) tumor suppressor (25% of cases), EGF receptor (EGFR) amplification or 
overexpression (~40-60% of cases), mutations of the phosphatase and tensin homology gene 
(PTEN) (30% of cases), deletion or inactivation of cyclin-dependent kinase inhibitors 
p16INK4a/p19ARF (30-40% of cases), amplification or overexpression of transformed 3T3 cell 
double minute 2 (MDM2) gene (10-50%), and loss of heterozygosity (LOH) on chromosome 10 
in 50-80% of cases. As a result of these genetic alterations, activation of signaling pathways 
such as PI3K Akt, Ras-MAPK and JAK/STAT (Janus Kinase/Signal Transducer and Activator 
of Transcription) leads to uncontrolled cellular proliferation and escape from apoptosis, which 
promotes tumor growth and progression. 
Several proteases such as MMP-9,MMP-2 and MMP-7 contribute to the invasiveness of GBM 
cells by altering the ECM of brain parenchyma (28). Studies have documented the presence of 
tumor cells not only in the normal brain tissue immediately surrounding GBM tumors but also in 
distant brain tissue including the contralateral hemisphere (29).  
The derogatory effects of tumor invasion are highlighted below (Figure 2). There is a presence of 
infiltrative cells even after surgical removal of bulk tumor (Figure 2C).  
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Picture modified from Medscape.com 
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Figure 2 Pre and post-operative MRI images of glioblastoma multiforme (GBM) tumor. (A) 
Pre-operative T1-weighted MRI scan of GBM tumor. The area of contrast enhancement (grey 
arrow) corresponds to frank tumor with disruption of the blood-brain barrier. The surrounding 
brain tissue into which GBM cells are invading is clearly edematous (black arrow). (B) Pre-
operative T2-weighted MRI scan of the same tumor. In this series, the frank tumor (grey arrow) 
and the surrounding brain tissue with edema and invading tumor cells (black arrow) are both 
bright. Note that the abnormal signal area extends across the corpus callosum into the 
contralateral hemisphere. (C) Post-operative T1-weighted MRI scan. The region of frank tumor 
has been resected resulting in the absence of contrast enhancement (grey arrow) but residual 
areas of edema and residual infiltrating tumor remain (black arrow) (30).  
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1.5 IL-1 Signaling 
Interleukin-1 (IL-1) is an important pro-inflammatory cytokine  associated with the host-defense 
response to injury and infection (31). It is a key regulator of both acute and chronic 
inflammation. It is an important mediator of inflammatory conditions in the CNS disorders 
including brain trauma, stroke, epilepsy, AD and PD (32, 33). The IL-1 family of cytokines 
consists of 11 related ligands, in which  IL-1β, IL-1α, IL-1 receptor antagonist (IL-1Ra), and IL-
18 are the most studied. IL-1α and IL-1β act as agonists and binds to the same type I receptor 
(IL-1R1). The IL-1R1 then associates with an accessory protein, IL-1R1AcP, and activates the 
downstream signaling cascades (34, 35). Subsequently, this leads to the production of  secondary 
inflammatory mediators  such as cytokines, chemokines and prostaglandins. IL-1R1 has a 
naturally occurring antagonist IL-1Ra , which is a soluble protein and competes with IL-1R and 
acts as a buffer for excess of IL-1 to inhibit downstream signaling (31, 35, 36). 
The level of IL-1 expression during normal physiological conditions in a healthy individual is 
very low. However, IL-1 expression is dramatically increased in response to injury as well as 
infections (31). In the CNS, IL-1 is mostly produced by activated microglia. Chemokines and 
cytokines released by activated microglia can then stimulate astrocytes, oligodendrocytes and 
even neurons to further produce IL-1 (33, 37, 38). Except microglia, all other cells of the CNS 
express IL-1R1 and therefore respond to IL-1 (31). 
IL-1, upon binding to its receptor, can activate numerous signaling cascades. In astrocytes, it is 
shown to activate the IKK-NF-κB pathway and  the mitogen-activated protein kinases  
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(MAPKs) p38 MAPK, JNK and ERK (39). This activation leads to increased cell proliferation 
and hypertrophic changes in morphology also known as reactive astrogliosis. The IL-1 activated 
astrocytes, produce VEGF as well as many other factors regulating angiogenesis, and vessel 
plasticity. In addition, IL-1 also modulates astrocyte migration which is critical for recovery and 
repair of the  injury site within the brain (40). In contrast, oligodendrocytes respond to IL-1 to 
promote their differentiation and maturation, indicating that IL-1 might have a role in the re-
myelination and repair process after injury (31, 41). 
Low level IL-1 expression in neurons is considered to regulate normal physiological functions 
including sleep, memory and long term potentiation. IL-1 concentration, and the duration of IL-1 
activation of neurons determines its effects. In contrast to astrocytes, IL-1 does not signal 
through MAPK, JNK and ERK1/2 activation in neurons; instead, it activates Src kinase (42, 43). 
Neurons are more vulnerable to neurotoxic effects from IL-1 secreted by activated glial cells. 
High levels of IL-1 causes both glia and neurons to produce various neurotrophic and growth 
factors that promote neuronal survival (44). In the neurons, high concentration of IL-1 activates 
the c-Rel subunit of NF-κB instead of RelA, hence is responsible for its protective effects (45). 
Knock-out mice lacking  IL-1α/β show protection to ischemic brain injury. Whereas, IL-1Ra (the 
antagonist) knock-out mice exhibit enhanced (3 fold) ischemic brain injury and caused increased 
mortality (36). IL-1 plays an important role is neuroinflammation as well as sterile inflammation  
and it can up-regulate various genes/factors that can lead to its toxic or protective effects during 
inflammation. 
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1.6 NF-κB pathway 
There are five members of the mammalian NF-κB family, p65 (RelA), RelB, c-Rel, p50/p105 
(NF-κB1), and p52/p100 (NF-κB2), that exist in unstimulated cells as homo or heterodimers 
bound to IKB family proteins. NF-κB proteins are characterized by the presence of a conserved 
300 amino acid Rel homology domain (RHD) that is located toward the N terminus of the protein 
and is responsible for dimerization, interaction with IκBs, and binding to DNA (Fig.2). Upon 
stimulation, IκB kinase complex causes phosphorylation of IκBs, which is followed by 
ubiquitination, degradation of IκB proteins. This leads to the release of NF-κB dimers that 
translocate to the nucleus, bind specific DNA sequence, promoting transcription of target genes 
(46).  
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Picture modified from- NF-κB in immunobiology. Matthew S Hayden and Sankar 
Ghosh. Cell Research. Feb 2011 
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Figure 3 Components of NF-κB pathway. The  mammalian Rel (NF-κB ) protein family 
consists of five members: p65 (RelA), RelB, c-Rel (Rel), and the precursor proteins p100 (NF-
κB 2) and p105 (NF-κB 1), the latter giving rise to p52 and p50, respectively. The IκB family 
consists of eight bona fide members, IκBα, IκBβ, IκBε, IκBζ, BCL-3, IκBNS, p100, and p105, 
which are typified by the presence of multiple ankyrin repeat domains. The IKK complex 
consists of IKKα  (IKK1 or CHUK), IKKβ (IKK2), and NEMO (IKKγ). Relevant domains 
typifying each protein family are indicated. (ANK) Ankyrin repeat domain; (DD) death domain; 
(RHD) REL homology domain; (TAD) transactivation domain; (LZ) leucine zipper  domain; 
(GRR) glycine-rich region; (SDD) scaffolding and dimerization domain; (ULD) ubiquitin-like 
domain; (Z) zinc finger domain; (CC) coiled-coil domain; (NBD) NEMO-binding domain; (a) a-
helical domain; (IBD/DimD) IKK-binding domain/dimerization do- main; (MOD/UBD) minimal 
oligomerization domain/ubiquitin-binding domain; (PEST) proline-rich, glutamic acid-rich, 
serine-rich, and  threonine-rich (46). 
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The trademark of the NF-κB pathway is its regulation by IκB proteins such as IκBα, IκBβ, IκBε, 
IκBζ, and IκBNS and the precursor proteins, p100 and p105 which contain a multiple ankyrin 
repeat domain. NF-κB  pathway is activated by phosphorylation of IκBs on conserved serine 
residues, termed as destruction box serine residues (DSGXXS), leading to recognition by bTrCP 
proteins. Once the phosphorylated destruction box is recognized it induces K48-linked 
polyubiquitination by the Skp1–Culin–Roc1/Rbx1/Hrt-1F-box (SCF or SCRF) family of E3 
ligases together with the E2 enzyme UbcH5. The most studied member of the family is IκBα, 
which is rapidly degraded during activation of canonical NF-κB signaling pathways, leading to 
the release of multiple NF-κB dimers, although the p65:p50 heterodimer is considered the 
primary target of IκBα. 
The NF-κB pathway has been classified into two types; canonical and non-canonical. Once the 
canonical pathway is triggered by various stimuli, it leads to the activation of IKKβ (also known 
as IKK2). IKKβ exists in a complex with the closely related kinase IKKα (also known as IKK1) 
and the regulatory protein NEMO (also known as IKKγ). Once activated IKKβ phosphorylates 
IκB proteins such as IκBα. In contrast to the classical NF-κB pathway, the non-canonical 
pathway depends on IKKα but is independent of NEMO. IKKα activation by these stimuli leads 
to phosphorylation of p100 and the generation of p52/RelB complexes (46).  
Some studies have shown the presence of RelB/p50 dimers, as a result of RelB induction by the 
canonical pathway. In addition, a recent study showed the presence of RelB/p50 dimers in the 
cytoplasm bound to IκBα and IκBε. This complex is regulated by the canonical  
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signaling pathway during dendritic cell (DC) maturation (47). These recent studies using 
mathematical modelling, combined with the careful kinetic analyses of IκB degradation, RelB 
activation and gene expression and the use of knockouts of various members of the IκB family 
presents a definitive rejection of the idea that RelB is regulated by non-canonical signaling 
alone.(47) 
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Picture modified from- A less-canonical, canonical NF-κB pathway in DCs. Matthew S 
Hayden. Nature Immunology 2012 
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Figure 4 A RelB canonical pathway in dendritic cells. The canonical NF-κB signaling 
pathway (left) comprises of a NEMO-dependent IKK complex that phosphorylates (P) IκB–NF-
κB complexes depicted by IκBα-p65-p50. IκB is then ubiquitinated (Ub) and degraded, allowing 
the NF-κB dimer to translocate to the nucleus and bind κB sites on the promoters of target genes. 
In the non-canonical or alternative pathway (right), different set of inputs induce the degradation 
of TRAF3, which leads to the stabilization of NIK and NIK-IKKα–dependent phosphorylation of 
p100 bound to RelB. Once phosphorylated the p100 protein is processed by the proteasome, 
releasing the RelB-p52 dimers, which translocate to the nucleus and bind κB sites.  
In DC, an additional third pathway in which overexpression of RelB and constitutive processing 
of p100 results in the formation of RelB-p50 complexes bound mainly by IκBα (and, to a lesser 
extent, by IκBε) in resting condition has been discovered. These RelB-p50 complexes are 
regulated by stimuli of the canonical pathway (47). 
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1.7 IL-6 signaling 
IL-6 and IL-6 related cytokines including LIF(Leukemia Inhibitory factor), CNTF (Ciliary 
Neurotrophic Factor), OSM are a group of pleiotropic cytokines that regulate immunomodulatery 
activities, inflammation and oncogenesis. These cytokines bind and cause heterodimerisation of 
individual receptors that include IL-6R, LIFR, CNTFR, OSMR with gp130 receptor subunit (48).  
This binding of ligand to receptor causes receptor associated tyrosine kinases, Janus kinases 
(JAK1, JAK2, JAK3 and Tyk2), to phosphorylate tyrosine residue within the cytoplasmic 
domain of gp130 subunit. This creates a docking site for src-homology-2 containing proteins, 
including STATS. STAT proteins are then tyrosine phosphorylated by JAKs, which leads to their 
dimerization and subsequent translocation to the nucleus. Once in the nucleus they recognize and 
bind to specific DNA elements in the promoter region of target genes (49). 
Many receptors with intrinsic tyrosine kinase activity (RTK’s) such as EFG, PDGF and non-
RTK’s such as src can also activate STAT proteins (50-52). There are 7 types of STAT proteins: 
STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6 (53). STATs form both homo 
and hetrodimers dependent on ligand types and stimulus strength. All STATS can form 
homodimers except STAT2. Heterodimers are made of STAT1 and STAT2 as well as STAT1 
and STAT3, whereas other STATs can form tetramer or higher ordered structure (53, 54).  
STATS can undergo various post-translational modifications including acetylation, 
phosphorylation, sumoylation, and ubiquitination, which regulates its transcriptional activity as 
well as biological response. Specifically, serine-727 phosphorylation within the transactivation  
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domain of STAT1 and STAT3 enhances their transcriptional activity without affecting DNA 
binding. Once the  phosphorylation mark is removed by nuclear phosphatases, such as TC45 in 
the case of STAT1 and STAT3, it favors the nuclear export of these proteins (55). Not only does 
JAK-STAT signaling regulate a plethora of physiological functions, but in turn itself it is under 
tight control of negative regulation at different levels. Several cytoplasmic tyrosine phosphatases 
such as SH2-containing phosphatases 1 (SHP-1), SHP-2 and protein tyrosine phosphatases 1B 
(PTP1B) dephosphorylate receptor and kinase phosphorylation sites, which disables the 
recruitment of SH2 domain containing proteins including STATs (56, 57). Suppressors of 
cytokine signaling (SOCS) proteins, which are a family of cytoplasmic inhibitors, that bind to the 
receptor sites and/or JAK catalytic sites to block further STAT activation. These molecules after 
being induced by cytokines can regulate the receptor protein turnover as well as that of 
associated molecules via ubiquitin-proteasome mediated degradation (58). In addition, there are 
some negative regulators of JAK-STAT signaling, such as protein inhibitors of activated stats 1 
(PIAS1) and PIAS3. PIAS1 and PIAS3 interacts with tyrosine phosphorylated STAT1 and 
STAT3, respectively, and block their DNA binding in vitro (53). 
 
1.8 Oncostatin M (OSM) 
OSM belongs to IL-6 family of cytokines. It is a secreted glycoprotein, expressed mainly by 
monocytes, macrophages and microglia, neutrophils, T-cells, osteoblast, dendritic cells and 
testes.(49). OSM signals through type I (gp130/LIFR), and type II (gp130/OSMRβ) receptor  
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complexes. OSM activates STAT1, 3, 5 ERK1/2 and p38.  
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Picture modified from-Oncostatin M: a pleiotropic cytokine in the central nervous 
system. Chen SH, Benveniste EN. Cytokine Growth Factor Rev. October 2004. 
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Figure 5 Proposed signaling pathways of OSM. (Top) OSM activation of the JAK/STAT 
pathway. Binding of OSM to its receptor subunits induces dimerization of receptor subunits, 
resulting in the phosphorylation and activation of JAKs. The activated JAKs phosphorylate (P) 
tyrosine residues (Y) on receptor subunits, providing docking sites for STATs. The STATs are 
recruited to the sites and are  
tyrosine phosphorylated by JAKs, followed by the homo or hetero dimerization of STATs. 
Dimerized STATs translocate into the nucleus, and bind to regulatory elements in DNA, and 
regulate gene expression. This process may be negatively regulated at multiple steps by 
PIAS and SOCS proteins. 
(Bottom) OSM activates the MAPK pathway. OSM can also signal through the MAPK pathway. 
OSM binding induces tyrosine phosphorylation on gp130, which leads to the recruitment of 
SHP2 (Src homology-2 domain containing protein tyrosine phosphatase) SHP2 then provides a 
docking site for the SH2 domain of the adaptor protein Grb2, which is complexed with the GTP- 
exchange factor SOS. SOS interacts with Ras, and Ras binding recruits Raf. Activated Raf then 
transmits its signal via the MAPKKK–MAPKK–MAPK cascade, leading to gene expression 
(49). 
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OSM is a cytokine with both pro- and anti-inflammatory actions (49). It is associated with host 
defense, as is expressed by activated T-cells, macrophages and microglia. In the CNS, OSM is 
detected only in MS and HAD (HIV associated dementia) patients where it localized to activated 
microglia, hypertrophic astrocytes and infiltrating leukocytes but it is absent in normal brain. 
OSM stimulates the expression of MMP-1, 3 in astrocytes and IL-6, MCP-1 and TIMP-1 in 
astrocytes and brain endothelial cells. 
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Chapter 2 
Materials and Methods 
2.1 Mice. 
The doxycycline (DOX)-inducible, brain-specific HIV-Tat1-86 transgenic mice have been 
described (59), C57BL/6 mice were obtained from Jackson Laboratory. All mice were housed at 
Virginia Commonwealth University according to guidelines of the Institutional Animal Care and 
Use Committee of Virginia Commonwealth University.  The mouse protocols were approved by 
the Institutional Animal Care and Use Committee. Male and female mice 8–16 weeks of age 
were used. 4-6 weeks old Athymic Nu/Nu were purchased from NCI. The animals were housed 
for 10 days before utilizing them for experimentation. 
 
2.2 Turpentine-induced inflammation. 
Turpentine abscesses were initiated by subcutaneous injection of pure gum spirits of turpentine 
(50 µl) into anesthetized age-matched male and female mice (6–8 weeks of age). Mice were 
killed after 8h and the skin and underlying muscles at the site of injection was collected for 
mRNA analysis. 
 
2.3 Experimental autoimmune encephalomyelitis (EAE). 
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Each mouse received intradermally 300 µg of MOG35–55 peptide (AnaSpec, Fremont, CA) 
emulsified in CFA containing 500 µg of Mycobacterium tuberculosis H37Ra (Difco, Detroit,  
MI) and intraperitoneally 200 ng of Pertussis toxin (Enzo Life Sciences, Farmingdale, NY). An 
additional dose of 200 ng of Pertussis toxin was administered two days post immunization. A 
booster dose MOG35–55/CFA/Mycobacterium tuberculosis H37Ra was given seven days post 
immunization. Mice were examined daily (the first day following booster injection was assigned 
as day 1), weighted, and the severity of the disease was quantitated using a five point scale: 0 – 
no symptoms, 1 – limp tail, 2 – limp tail with loss of righting, 3 – paralysis of single hind limp, 4 
– paralysis of both hind limps, and 5 – death. 
 
2.4 Irradiation 
Irradiations were carried out using a MDS Nordion Gamma-cell 40 research irradiator with a 
137Cs source delivering a dose of 1.05 Gy/min to the head only. Mice received a dose of 20 Gy. 
 
2.5 Clinical samples. 
Biopsy samples of oligodendroglioma tumors were obtained from VCU’s brain tumor bank 
(Department of Neurosurgery, Richmond, VA). Normal cortical tissue samples were obtained 
from healthy brain regions of patients with oligodendroglioma or epileptic patients. The biopsy 
samples represent primary grade II and III, and recurrent tumors. All of the oligodendroglioma 
samples expressed significant amounts of myelin basic protein (data not shown), confirming the 
oligodendroglial origin of these tumors. 
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2.6 Cell culture. 
Human glioblastoma U373-MG cells were obtained from American Type Culture Collection 
(Manassas, VA). Mouse astrocytes were prepared as described (59) Human cortical astrocytes 
were prepared from fetal tissue provided by Advanced Bioscience Resources and were cultured 
as previously described (60, 61).  Cells were stimulated with 25 ng/ml IL-1, 25 ng/ml OSM, 25 
ng/ml IL-6, or 25 ng/ml sIL-6R (all from R&D Systems, Minneapolis, MN).  Cell Culture 
The U1242 glioma cells were obtained from Dr. Kristoffer Valerie. The U1242 LG (Luciferase 
GFP-Green fluorescent protein) cells and variants were produced as described in 2.15. The 
U1242 and U1242 LG cells were cultured in Dulbecco's modified Eagle's medium supplemented 
with 10% fetal calf serum, antibiotics, sodium pyruvate, and nonessential amino acids. The 
lentiviral infected cells, received an additional Puromycin (1µg/ml) in their growth media. 
 
2.7 Knock-down of target genes. 
Expression of RelB, cRel, p50, STAT3, p65, YKL-40 and p52 mRNAs was down-regulated 
using SmartPool siRNAs transfected into astrocytes using Dharmafect 1 (all from Dharmacon, 
Lafayette, CO). 
 
2.8 Quantitative PCR. 
Total RNA was prepared utilizing the TRIzol (Life Technologies, Carlsbad, CA). 1 μg of RNA 
was reverse-transcribed using the high capacity cDNA Archive kit (Life Technologies).  
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Premixed primer-probe sets and TaqMan Universal PCR Master Mix (Life Technologies) were 
employed to examine mRNA levels. cDNAs were diluted 10-fold (for the target genes) or 100-
fold (for GAPDH) and amplified using the ABI7900HT cycler. Gene expression levels were 
normalized to GAPDH and presented as a fold induction with the mean values ± standard 
deviation. A Power SYBRGreen PCR kit (Life Technologies) was used for chromatin 
immunoprecipitation qPCR assays as previously described (25).  
 
2.9 Western Blotting. 
The cells were lysed in 10 mM Tris, pH 7.4, 150 mM sodium chloride, 1 mM EDTA, 0.5% 
Nonidet P-40, 1% Triton X-100, 1 mM sodium orthovanadate, 0.2 mM PMSF, and protease 
inhibitor mixture (Roche Applied Science, Indianapolis, IN). Samples were separated using 
SDS-PAGE and transferred onto nitrocellulose membranes (Schleicher & Schuell, Dassel, 
Germany). The anti-YKL-40, anti-RelB, anti-p65, anti-p50, anti-β-tubulin, and anti-GAPDH 
antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and anti-Stat3 
antibody was obtained from Cell Signaling Technology (Danvers, MA). Antigen-antibody 
complexes were visualized by enhanced chemiluminescence using Immobilon Western blotting 
kit (Millipore, Temecula, CA). 
 
2.10 Coimmunoprecipitation 
200–300 μg of protein lysates, prepared as described above, were pre-cleared with 10 μl of the  
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protein G-Sepharose beads (GE Healthcare, Pittsburgh, PA) for 1h. The lysates were then 
incubated with 2 μg of anti-RelB or anti-p50 antibodies overnight at 4°C, 25μl of protein G-
Sepharose beads were added, and incubated for 1 h at 4°C.  The beads were washed extensively 
with the lysis buffer, and immunoprecipitated proteins were eluted in sample buffer at 95 °C for 
5 min. 
 
2.11 Synthetic Oligonucleotides. 
The following oligonucleotides were synthesized to introduce mutations in the YKL-40 
promoter: -669 NF-ΚB , 5’-CTGAATTCGATAGCTGTCTTTCCCTCTAA-3’ and 5’-
ACAGCTATCGAATTCAGAATGCTTTAAGC-3’; -717 NF-ΚB , 5’-ATCTCGAGAATAAA 
ACAGAAGCAAAAT AG-3’ and 5’-TTATTCTCGAGATAAAGAGAGAGGATCTT-3’. 
Following oligonucleotides were used in EMSA: -669 NF-ΚB  probe, 5’-GATCTTTCTTGG 
GAATTTCCCTGTCA-3’ and 5’-GATCTGACAGGGAAATTCCCAAGAAA-3’; -717 NF-ΚB  
probe, 5’-GATCTCTTTATGGGAATTTCAAAACAA-3’ and 5’-GATCTTGTTTTGAAA 
TTCCCATAAAGA-3’. 
 
2.12 Nuclear Extracts and EMSA. 
Nuclear extracts were prepared as previously described (62). Double-stranded DNA fragments 
were labeled by filling in the 5’-protruding ends with Klenow enzyme using [α-32P] dCTP (3000  
 
 
 
 
 
34 
 
Ci/mmol). Briefly, 5 µg of nuclear extracts and ∼10 fmol (10,000 cpm) of probe were utilized. 
Anti-RelB, anti-p50, anti-p65 (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies were used 
for supershift studies. 
 
2.13 Chromatin Immunoprecipitation (ChIP) Assay. 
ChIP assays were performed as described previously (25) with the following exceptions. The 
cells were cross-linked with 1% formaldehyde for 10 min at 37 °C and then washed with ice-cold 
PBS containing 125 mM glycine. RelB and p50 antibodies or none-immune rabbit serum were 
used to precipitate cross-linked proteins. The following primers to the YKL-40 promoter were 
used in the qPCR: 5’-GTGCAGCCGCCCCGTAG-3’ and 5’-GCCTGAAACTGAGCGCTCC-
3’. 
2.14 Plasmids and transfections. 
The pYKL(-1300)Luc reporter was provided by Dr. Michael Rehli (University of Regensberg, 
Regensberg, Germany) (11). The site-directed mutagenesis was performed using QuikChange II 
site-directed mutagenesis kit (Stratagene, La Jolla, CA) and the oligonucleotides described above 
and mentioned before (25). Plasmids expressing dominant negative IκBα and constitutively 
active STAT3 were described before (25). Human astrocytes were transiently transfected in 12-
well clusters using the FuGENE6 transfection reagent (Roche Applied Science). Twenty four 
hours post-transfection, the cells were stimulated with IL-1 or OSM for 20h and cell extracts 
were prepared. Luciferase assays were performed using a dual luciferase reporter assay kit  
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(Promega Corporation, Madison, WI). Luciferase activities were normalized to Renilla luciferase 
activities. GIPZ plasmid containing shRNA to YKL-40 was purchased from Thermo-scientific 
Open Biosystems. The shRNA-YKL-40 was cloned into an inducible TRIPZ vector (inducible 
RFP expression ). The pTRIPZ (Thermo-scientific) has a Tet (Tetracycline/Doxycycline) 
inducible shRNA expression and it permits reversible and regulatable gene knockdown. 
 
2.15 Lentiviral Infection. 
The U1242GL cells were obtained by  infecting U1242 with infected with lentivirus expressing 
pTRIPZ which contained either scrambled shRNA or shRNA to YKL-40) packaged in a 
Lentiviral vector. The cells were then infected with  LP-hLuc- lv201 (Genocopia), comprising of 
a eGFP and PAC (Puromycin resistance) gene. These cells were then selected in media with 
puromycin (1µg/ml) and were FACS sorted to obtain the two cell population expressing 
comparable GFP levels. 
 
2.16 Wound Healing Assay. 
The cells were plated in 6-well plates (3×105 cells/well for U1242 cells to obtain a single 
confluent monolayer. Twenty-four hours later, media from each well were removed and stored in 
labeled eppendorf tubes. Subsequently, scratches were made using 20μl sterile pipette tips, 
followed by washing of the wells either by PBS or fresh media, to remove the cell debris from 
the scratch. This was followed by adding back the original media from each well. The cells were  
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then stimulated at different stimulants as described in the figure legend. Pictures of the wounded  
area (six fields/well) were taken at time points mentioned in the respective figure legends. The 
number of cells that migrated in the wound area were counted in each field, and the data are 
presented as the cells migrated per field. The experiments were repeated twice. In the case of 
siRNA experiments, 2×105 cells/well were plated followed by siRNA treatment for 30 hrs, and 
subsequently scratches were made. 
 
2.17 Transwell Migration Assay. 
Transwell migration was measured using a modified Boyden chamber using polycarbonate filters 
(25×80 mm, 12-μm pore size, Neuro Probe Inc, MD) coated with fibronectin. First the cells were 
added to the upper chamber at 5×104 cells/well were allowed to migrate. After 8 hrs, the excess 
cells on the upper membrane surface were removed using cotton swabs, and the cells that 
migrated through the pores and spread on the lower surface of the filter were fixed with methanol 
and then stained with Diff-Quik (Fisher). The cells that migrated were counted using an inverted 
microscope with a 10X objective. Each data point is the average number of cells in six random 
fields and is the mean ± S.E. of three to six individual wells. 
 
2.18 Invasion Assay. 
The assays were performed exactly as described above in the Transwell migration assay section 
the only exception being that the filters were coated with Matrigel and not fibronectin. 
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2.19 Xenograft.  
The stereotactic techniques used to implant glioma cells have been previously described(63). 
Briefly, cells were trypsinized, the pellet was then re-suspended in Matrigel at 1:1 ratio to obtain 
5x104 cells/µl and then 1µl of cells (about 5x104 cells) was implanted in the right striatum of the 
mouse (seven animals/each group). All procedures have been approved by the Virginia 
Commonwealth Universities Animal Care and Use Committee protocols. The mice were checked 
regularly for post-operative morbidity, morbundity and neurological deficits. The tumor-bearing 
animals were imaged with Caliper IVIS 200Xenogen every week from week 1 to 4 post-
implantation and sacrificed 30 days after post-implantation Bioluminescence imaging (BLI) of 
the tumors was done using after subcutaneous injection of D-luciferin (Gold Biotechnology) at a 
concentration of 30 mg/mL in PBS. Post-mortem animals were perfused with 4%PFA. Brains 
were removed, allowed to sink in sucrose for 24-48 hours, and embedded in OCT thereafter.   
 
2.20 Immunohistochemistry. 
The brain tumor samples were sectioned (6 µm), and stained with haematoxylin and eosin 
(H&E) at The Tissue and Data and Acquisition and Analysis Core (TDAAC) at VCU. 10 µm 
sections were used for Immunohistochemistry utilizing anti-RFP (Rockland, Pennsylvania) and 
Hoechst stain (Life technologies). The slides with brain sections, were fixed with acetone, 
followed by permeabilization with 1% Triton-X-100/PBS and blocked with 10% normal goat  
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serum in Triton-X-100/PBS before the exposure to primary antibodies followed by secondary 
antibodies. The sections were then incubated with anti-RFP overnight (primary). The section 
were then washed with wash buffer (0.01% Triton-X) (3x,5min ). Secondary antibody 
conjugated to (Alexa-546) was added in wash buffer with 1% goat serum, and incubated at RT 
for 1 hour, followed by washing. The slides were then, stained with Hoechst nuclear stain for 5 
min at RT, followed by 3 more washes, after which they were sealed using a coverslip and vecta-
sheild (Vector Labs, CA). Whole brain (tiled images) were obtained using a Applied Imaging 
Ariol SL-50 system (Applied Imaging Corp.). All brain tumor sections were analyzed for 
invasion. The maximum distance between the center of tumor mass and the infiltrating cells 
(single or cluster cells) at the edge was measured by Image Pro 4.5 as described before (28). The 
mean of maximum distance was calculated from seven different infiltrating single cells/clusters 
per animal and seven different xenografts per group.  
 
2.21 Statistical analysis. 
All experiments were repeated at least three times with consistent results. Data are presented as 
mean ± SD or SEM (as noted in figure legends). For mouse studies, four to seven randomly 
chosen mice were used per experimental group. SPSS Statistics 21 software was used for 
statistical analyses. A Bonferroni post-hoc test was used for one-way ANOVA comparisons, 
with a P value of <0.05 being considered statistically significant. Independent sample Student's t-
test was used for unpaired observations. 
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Chapter 3 
 
Sterile inflammation-associated expression of YKL-40 is regulated by 
RelB/p50 complexes 
3.1 Abstract 
Secreted protein YKL-40 has been proposed as a biomarker of a variety of human diseases 
characterized by ongoing inflammation, including chronic neurological pathologies such as 
multiple sclerosis (MS) and Alzheimer’s disease. However, inflammatory mediators and the 
molecular mechanism responsible for enhanced expression of YKL-40 remained elusive. Using 
several mouse models of sterile inflammation, we now show that YKL-40 expression correlated 
with increased expression of both IL-1 and IL-6. Furthermore, IL-1 together with IL-6 or the IL-
6 family cytokine oncostatin M (OSM), synergistically up-regulated YKL-40 expression in both 
primary human and mouse astrocytes in vitro. The robust cytokine-driven expression of YKL-40 
in astrocytes required both STAT3 and NF-κB  binding elements of the YKL-40 promoter. 
Additionally, YKL-40 expression was enhanced by constitutively active STAT3 and inhibited by 
dominant-negative IκBα. Surprisingly, cytokine-driven expression of YKL-40 in astrocytes was 
independent of the p65 subunit of NF-κB  and instead required subunits RelB and p50. 
Mechanistically, we show that IL-1-induced RelB/p50 complex formation was further promoted 
by OSM and that these complexes directly bound to the YKL-40 promoter. Moreover, we found 
that expression of RelB was strongly up-regulated during sterile inflammation in vivo and by IL-
1  
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in astrocytes in vitro. We propose that IL-1 and the IL-6 family of cytokines regulate YKL-40 
expression during sterile inflammation via both STAT3 and RelB/p50 complexes. These results 
also indicate that IL-1 regulates the expression of a subset of specific anti-inflammatory genes in 
non-lymphoid tissues during sterile inflammation via the canonical activation of the RelB/p50 
complexes.  
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3.2 Introduction 
In the past several years YKL-40 (also known as chitinase 3-like protein 1, human 
cartilage glycoprotein 39, and breast regression protein 39) has attracted growing attention as a 
marker of ongoing inflammation and oncogenic transformation (64). This secreted glycoprotein, 
expressed in both invertebrates and vertebrates, belongs to the 18-glycosyl-hydrolase family of 
proteins but lacks glycolytic activity (65, 66). Although its biological functions are not fully 
understood, it is expressed by many cell types, including macrophages, neutrophils, 
synoviocytes, chondrocytes, smooth muscle cells, endothelial cells, microglia, and astrocytes, 
suggesting that its biological effects are not restricted to a particular cell type. Indeed, YKL-40 
stimulates proliferation of synoviocytes and chondrocytes (67), promotes adhesion and migration 
of vascular smooth muscle and endothelial cells (68-70), and is a migration factor for astrocytes 
(25). Surprisingly, unchallenged YKL-40 knockout mice appear normal; however, when 
challenged with antigen they display impaired Th2-dependent immune responses, show 
diminished fibrosis and tissue inflammation, decreased accumulation of M2 macrophages, and 
increased apoptosis of CD4+ T cells and macrophages (14). In contrast, these mice display an 
exacerbated response to experimental autoimmune encephalomyelitis (EAE) (71) and enhanced 
inflammatory responses to hyperoxia (72), suggesting that YKL-40 differentially affects 
inflammatory responses depending on the type of immune activation and tissue involved. In 
agreement with the role of YKL-40 during inflammatory responses in mice, YKL-40 levels are 
elevated in patients with a wide array of human diseases characterized by ongoing inflammation, 
including rheumatoid arthritis, atherosclerosis, type 2 diabetes, pelvic inflammatory disease, 
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chronic pancreatitis and secondary diabetes, severe pediatric asthma, cirrhosis, Crohn’s disease, 
and others (73-80). Elevated levels of YKL-40 are also present in the cerebrospinal fluids of 
patients with a variety of acute and chronic neurological pathologies, such as MS, Alzheimer 
disease, viral encephalitis, HIV-associated dementia, brain infarction, and traumatic brain injury 
(22-24, 81), with activated microglia and reactive astrocytes both producing YKL-40 in the 
central nervous system. Thus, over the last decade it become evident that elevated YKL-40 
expression correlates with both infection-induced inflammation and sterile inflammation, a 
paradigm triggered by physical, chemical or metabolic noxia. Accordingly, YKL-40 is also 
expressed by several solid tumors, such as osteosarcoma, ovarian carcinoma and glioblastoma 
multiforme (GBM) (9, 10), and promotes angiogenesis and radioresistance of GBM tumors and 
angiogenesis of breast and colon cancer cells (18, 82). Since elevated expression of YKL-40 
correlates with ongoing inflammation that is a component of many diseases, YKL-40 has been 
proposed as a biomarker for many pathologies, including cardiovascular disease, asthma, 
arthritis, MS, Alzheimer disease, and many cancers, including GBM, melanoma, hepatocellular 
carcinoma, breast and pancreatic cancers (10, 81). 
Despite the numerous reports documenting elevated expression of YKL-40, relatively 
little is known about the inflammatory mediators and specific molecular mechanisms that control 
its expression. Pro-inflammatory cytokines, including TNF and IL-1, induce expression of YKL-
40 in chondrocytes (13) and astrocytes (25); however, to a much lower extent than the 
conditioned media of macrophages (83). Both IL-1 and TNF are known to trigger a classical IκB 
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kinase (IKK)γ-dependent activation of NF-κB , which involves IKKβ-mediated phosphorylation 
and subsequent degradation of IκBs, followed by the release and subsequent nuclear 
translocation of the p65/p50 NF-κB  complexes (84). In contrast, these cytokines do not activate 
a non-canonical IKKγ-independent NF-κB  pathway, which involves NF-κB -inducing kinase 
(NIK), IKKα-dependent processing of NF-κB 2 p100, and generation of RelB/p52 complexes 
(85-87). Concordantly, the p65/p50 complex has been proposed to mediate TNF- and IL-1-
induced YKL-40 expression in chondrocytes (13). In contrast however, p65/p50 has also been 
shown to recruit histone deacetylases-1 and -2 to the YKL-40 promoter and repress its 
expression in response to TNF in GBM cells (15). In addition, IL-6 and OSM moderately 
upregulate YKL-40 expression in human astrocytes, which requires STAT3 and formation of a 
complex between STAT3 and nuclear factor I-X3 on the YKL-40 promoter (25). However, 
profound activation of YKL-40 expression observed during ongoing inflammatory processes in 
vivo has not been adequately recapitulated in the in vitro experiments. Therefore in this study, we 
set up experiments to identify molecular mechanisms that govern YKL-40 expression during 
sterile inflammation.  
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3.3 Results 
3.3.1 Sterile inflammation induces YKL-40, IL-1 and IL-6 expression.  
To model the induction of YKL-40 expression during sterile inflammation, we first employed a 
turpentine mouse model of irritant-induced acute inflammation, which is IL-1R-dependent (88). 
Turpentine causes tissue destruction at the site of injection, local cytokine production, and 
infiltration of pro-inflammatory cells (61). The local reaction is subsequently followed by a 
systemic response, including the production of acute phase proteins in the liver (89). Indeed, 
YKL-40 mRNA expression was robustly activated in tissues surrounding the site of turpentine 
injection and its induction was accompanied by a very strong induction of both IL-1 and IL-6 
mRNAs (Fig. 6). To corroborate these findings in the central nervous system model of sterile 
inflammation, expression of YKL-40, IL-1, and IL-6 was subsequently analyzed using a mouse 
EAE model of MS.  Immunization of mice with MOG35-50 peptide resulted in the induction of 
EAE, and modest upregulation of YKL-40 expression in the spinal cords of animals (Fig.7). The 
magnitude of YKL-40 induction was comparable to the results previously reported by others 
(71). In addition, expression of both IL-1 and IL-6 was also enhanced.  We also found an 
increase in the expression of glial fibrillary acidic protein (GFAP), which indicated activation of 
astrocytes in EAE as reported previously (90). Subsequently, we analyzed expression of YKL-
40, IL-1 and IL-6 in the brains of mice exposed to gamma irradiation, which is known to induce 
inflammation (91). In agreement with the turpentine and EAE data, levels of YKL-40, IL-1, and  
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IL-6 mRNAs were significantly higher in the irradiated brains (Fig. 8). We also used the HIV 
transactivator of transcription (TAT) transgenic mouse model in which induction of TAT protein 
expression in the brain induces local sterile inflammation and enhances expression of IL-1 and 
IL-6 (92). Using the TAT model, we found that YKL-40 expression was also enhanced upon 
activation of TAT expression (Fig. 9). Lastly, we analyzed samples of human oligodendroglioma 
tumors and found that the expression of YKL-40, IL-1, and IL-6 was strongly induced in 
comparison to normal brain (Fig. 10). We conclude that YKL-40 expression is enhanced during 
sterile inflammation, which coincides with the increased expression of IL-1 and IL-6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47 
 
 
 
 
 
Figure 6 Turpentine associated Sterile inflammation induces YKL-40, IL-1 and IL-6 
expression. Mice were injected s.c. with 50 µl turpentine or PBS (n=6). Tissue at the site of 
injection was collected after 8h and the expression of YKL-40, IL-1 and IL-6 mRNA was 
analyzed by qPCR.  
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Figure 7 YKL-40, IL-1, IL-6 and GFAP expression is up-regulated during EAE. EAE was 
induced in mice (n=6) and scored as described in methods section (left panel). The expression of 
YKL-40, IL-1, IL-6 and GFAP mRNA was analyzed in spinal cords by qPCR (right panels).  
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Figure 8 YKL-40 expression is up-regulated in the brain in response to irradiation. 
Expression of YKL-40, IL-1 and IL-6 was analyzed in the hippocampus of control (CON) or irradiated 
(IR) mice after 24 h. 
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Figure 9 YKL-40 expression is up-regulated in HIV-TAT transgenic mice. Tat expression was 
induced by DOX in Tat transgenic mice and the expression of YKL-40 mRNA was analyzed by qPCR 
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Figure 10 YKL-40, IL-1, and IL-6 expression is up-regulated in Oligodendroglioma 
patients. Expression of YKL-40, IL-1 and IL-6 mRNA was analyzed by qPCR in biopsies of 
oligodendroglioma tumors (OD) and healthy brain tissue. Median values are indicated. 
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3.3.2. IL-1 and OSM synergistically induce YKL-40 expression in astrocytes. In the nervous 
system, both astrocytes and microglia express YKL-40 (24, 25) and these cell types also respond 
to a broad range of inflammatory stimuli (93). We used astrocytes as model cells to study 
activation of YKL-40 expression during sterile inflammation. Primary human astrocytes were 
stimulated with IL-1 and IL-6 together with soluble IL-6 receptor (sIL-6R) (due to the fact that 
human fetal astrocytes express limited amount of IL-6R (60)). We also included OSM, a member 
of IL-6 cytokine family that signals via OSM receptors abundantly expressed by astrocytes.  
Although IL-1, IL-6/sIL-6R, or OSM alone only moderately activated YKL-40 mRNA 
expression, stimulation of astrocytes with IL-1 together with OSM resulted in synergistic 
activation (Fig. 2A). Since IL-1-treated astrocytes express IL-6, their costimulation with IL-1 
and sIL-6R also caused synergistic induction of YKL-40 expression; however, to less extent than 
OSM alone. Similar effects of IL-1 and OSM on YKL-40 expression were also observed at the 
protein level (Fig. 11A, insert) and in mouse primary astrocytes (Fig. 11B). These data together 
with our in vivo studies suggest that YKL-40 expression is coordinately regulated by IL-1 and 
cytokines of the IL-6 cytokine family during sterile inflammation. 
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Figure 11 Pro-inflammatory cytokines induce YKL-40 expression in astrocytes. Primary 
human (A) and mouse (B) astrocytes were stimulated with IL-1, IL-6, OSM and sIL-6R for 18h 
and expression of YKL-40 mRNA was analyzed by qPCR. Secreted YKL-40 was analyzed by 
western blotting in the culture medium (insert). ***P < 0.001 (one-way ANOVA). 
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3.3.3. STAT3 but not p65 (NF-κB) regulate cytokine-induced YKL-40 expression. NF-κB 
and STAT3 are the major transcription factors activated by IL-1 and OSM, respectively (84, 94). 
Since p65 subunit of NF-κB and STAT3 were previously implicated in cytokine-induced 
expression of YKL-40 (15, 25), their expression was knocked down in human astrocytes. 
Downregulation of STAT3 (Fig. 3C) dramatically diminished IL-1/OSM-induced YKL-40 
expression (Fig. 12A). Surprisingly, knockdown of p65 had no effect on YKL-40 expression 
(Fig. 12A), but did drastically diminish the expression of IL-8, which is p65-dependent (Fig. 
12B). To identify the mechanism of cytokine-induced YKL-40 expression, putative NF-κB , 
STAT3 and activatory protein 1 (AP-1) binding sites of the YKL-40 promoter were mutated and 
the generated reporters were analyzed in astrocytes (Fig. 12D). Although cytokine-driven 
expression of YKL-40 is p65-independent (Fig. 12A), mutation of the proximal NF-κB site (-669 
to -660 bp) alone substantially diminished activation of the reporter, whereas mutation of the 
distal NF-κB site (-717 to -708 bp) alone had no effect (Fig. 12D). In addition, mutation of the 
STAT3 and AP-1 sites also drastically diminished reporter activity. In another approach, we 
overexpressed dominant-negative IκBα and constitutively active STAT3 and analyzed 
expression of the YKL-40 reporter (Fig. 12E). Constitutively active STAT3 enhanced, whereas 
dominant-negative IκBα diminished cytokine-responsiveness. Collectively, these results suggest 
that the proximal NF-κB and STAT3 elements of the YKL-40 promoter are required for full 
responsiveness to IL-1 and OSM; however and in contrast to previous reports (15), p65 is 
dispensable for this response. 
 
 
 
 
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
 
 
 
Figure 12 Induction of YKL-40 expression by IL-1 and OSM is STAT3-dependent but p65-
independent. Human astrocytes were transfected with the indicated siRNAs. Forty hours post 
transfection, cells were stimulated with IL-1 and OSM for 18 hours and expression of YKL-40 
(A), IL-8 (B), and STAT3 (C) was analyzed by qPCR. (D) Astrocytes were transfected with the 
indicated reporters, stimulated with IL-1 and OSM for 18 hours, and luciferase and renilla 
activities were determined. Data are presented in comparison to the induced wild-type reporter 
(set as 100%). (E) Astrocytes were transfected with pYKL(-1300)Luc and plasmids expressing 
either vector, dominant-negative IκB (IκBSR), or constitutively-active (CA-STAT3). Cells were 
stimulated with IL-1 and OSM for 18 hours and processed as described in D. **P < 0.01 and 
***P < 0.001 (one-way ANOVA). 
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3.3.4. RelB and p50 regulate cytokine-induced YKL-40 expression. To determine which 
component of the NF-κB  complex regulates cytokine-driven YKL-40 expression, expression of 
p65, cRel, RelB, p50 and p52 was effectively knocked-down in astrocytes (Fig. 13B). 
Knockdown of either RelB or p50 significantly diminished cytokine-induced YKL-40 
expression, whereas knockdown of p65, cRel and p52 had no effect (Fig. 13A). This finding 
implicates both RelB and p50 in YKL-40 regulation. Interestingly, although human astrocytes 
constitutively express low levels of RelB (Fig. 13B), IL-1 induced dramatic RelB protein 
accumulation in these cells (Fig. 14A). Similarly, RelB mRNA expression was also up-regulated 
by IL-1 in mouse astrocytes (Fig. 14B). RelB expression was also strongly activated in vivo by 
turpentine in an IL-1-dependent model of irritant-induced sterile inflammation (Fig. 14C). 
Cumulatively, these data suggest that increased expression of RelB may drive cytokine-mediated 
YKL-40 expression in vitro and in vivo.  
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Figure 13 Cytokine-induced RelB/p50 complexes regulate YKL-40 expression. Human 
astrocytes were transfected with the indicated siRNAs. Forty hours post transfection, cells were 
stimulated with IL-1 and OSM for 18 hours. Expression of YKL-40 (A) and p52 (B, bottom 
panel) was analyzed by qPCR. Expression of p65, RelB, p50 and β-tubulin was analyzed by 
western blotting (B, left panel).  
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Figure 14 Pro-inflammatory cytokines induce RelB expression. (A) Human astrocytes were 
stimulated with IL-1 and OSM for the indicated times and expression of RelB and GAPDH was 
analyzed by western blotting. (B) Mouse astrocytes were stimulated with IL-1 and OSM for 18 
hours and expression of RelB was analyzed by qPCR. (C) Mice were injected i.c. with 50 µl 
turpentine or PBS (n=6). Tissue at the site of injection was collected after 24h and the expression 
of RelB mRNA was analyzed by qPCR. **P < 0.01 and ***P < 0.001 (one-way ANOVA). 
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3.3.5. RelB/p50 complexes bind to the YKL-40 promoter.  To determine whether RelB 
regulates YKL-40 expression directly or indirectly, binding of RelB and p50 to the YKL-40 
promoter was analyzed by ChIP (Fig. 16B). These experiments were performed in U373 glioma 
cells, which similarly to human and mouse astrocytes, up-regulate expression of both YKL-40 
(Fig. 15A) and RelB (Fig 16B) in response to IL-1 and OSM, and this cytokine-induced 
expression is diminished by the knockdown of p50 and RelB. Although RelB and p50 did not 
bind to the YKL-40 promoter in unstimulated U373 cells, binding of RelB and p50 was apparent 
in cytokine-treated cells (Fig. 16B), suggesting that RelB/p50 complexes directly regulate YKL-
40 expression. To determine if IL-1/OSM-treatment induces RelB/p50 binding to the previously 
identified NF-κB  sites, EMSAs were performed using oligonucleotides containing distal and 
proximal NF-κB  sites. In agreement with the mutational analysis that showed the importance of 
the proximal NF-κB  site (Fig. 12D), strong protein binding to the proximal but not distal NF-κB  
site of the YKL-40 promoter was induced by IL-1 alone or together with OSM (Fig. 16C). 
Cytokine-induced proteins that bound to the proximal NF-κB  element in vitro included 
complexes that were supershifted with anti-p65, anti-RelB and anti-p50 antibodies (Fig. 16D), 
indicating that the proximal NF-κB  site can bind both p65/p50 and RelB/p50 complexes. We 
conclude that RelB/p50 complexes can directly bind to the proximal NF-κB  site of the YKL-40 
promoter. 
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Figure 15 Analysis of YKL-40 expression in U373 glioma cells. U373  were stimulated with 
IL-1 and OSM for18h and expression of YKL-40 mRNA was analyzed by qPCR (A) and RelB 
protein expression by western blotting (C). (B) U373 cells were transfected with the indicated 
siRNAs. Forty hours post transfection, cells were stimulated with IL-1 and OSM for 18 hours. 
Expression of YKL-40 was analyzed by qPCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
71 
 
 
 
 
 
 
 
Figure 16 RelB/p50 complexes bind at the distal NF-κB  site of YKL-40 promoter. (A) 
YKL-40 promoter. NF-κB  sites are indicated by grey boxes. Positions of ChIP primers (ChIP) 
and probes used in EMSA (-717 and -669 probe) are indicated. (B) ChIP was performed using 
chromatin prepared from U373 cells treated with IL-1 and OSM for 2h. Binding of p50 and RelB 
to the YKL-40 promoter was analyzed using the antibodies described in the experimental 
procedures. NRS indicates normal rabbit serum used for immunoprecipitation. Results are shown 
as normalized binding (binding of NRS-immunoprecipitated untreated samples were set as 1). 
Experiments were performed three times. *P < 0.05 and ***P < 0.001 (two-way ANOVA). (C-
D) Nuclear extracts were prepared from U373 and glioma cells stimulated with IL-1 and OSM 
for 8 hours. The binding was then analyzed by EMSA using the 32P-labeled oligonucleotide 
probes derived from the 5’ flanking region of the YKL-40 (-717 NF-κB  and -669 NF-κB , as 
indicated). (C) Binding to the -717 NF-κB  and -669 NF-κB  elements in U373 glioma cells. (D) 
Binding to the -669 NF-κB  probe in U373 cells. Specific antibodies or NRS were added to the 
binding reaction. 
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3.3.6. OSM enhances IL-1-induced RelB/p50 heterodimer formation. OSM efficiently 
regulated YKL-40 expression via STAT3 (Fig. 12) and also promoted the recruitment of p50 to 
the YKL-40 promoter (Fig. 16). Since YKL-40 expression depends on RelB/p50 (Fig. 13), we 
subsequently asked whether OSM promotes formation of IL-1-induced RelB/p50 heterodimer.  
RelB and p50 were immunoprecipitated from cytokine-treated cells and analyzed for the 
presence of co-immunoprecipitated RelB and p50 (Fig. 17). Indeed, p50/RelB complexes were 
formed in response to IL-1. More importantly, OSM significantly enhanced IL-1-induced 
formation of p50/RelB complexes. These data suggest that in addition to STAT3 activation, 
OSM enhances YKL-40 expression by promoting formation of p50/RelB complexes, which bind 
to the YKL-40 promoter. 
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Figure 17 OSM enhances IL-1-induced RelB/p50 heterodimer formation. Human astrocytes 
were stimulated with IL-1 or OSM for 8 hours, p50 or RelB were immunoprecipitated, and co-
immunoprecipitated p50 and RelB were detected by western blotting, as indicated. Expression of 
RelB and p50 in the lysates is shown the lower panels (lysate).   
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3.4 Discussion 
Although YKL-40 is upregulated in a broad range of human diseases associated with ongoing 
sterile inflammation, its biological functions still remain elusive. Nevertheless, exacerbated EAE 
(71) and enhanced responses to hyperoxia (72) in YKL-40 knock-out mice suggest that cytokine-
induced YKL-40 is needed for the proper resolution of inflammation. Once inflammation is 
resolved, YKL-40 expression ceases. In contrast, chronic inflammation leads to continuous 
aberrant upregulation of YKL-40 expression, which is continuously driven by pro-inflammatory 
cytokines. Our data from the turpentine, TAT-overexpression, and EAE mouse models together 
with human oligodendroglioma data, demonstrate that YKL-40 expression correlates with the 
expression of both IL-1β and IL-6. Importantly, IL-1α and IL-1β are both critical initiators of 
sterile inflammation released in response to broad range of danger associated molecular patterns.  
IL-1β is processed from its inactive precursor in response to inflammasome activation and 
subsequently secreted from activated cells, while active intracellular IL-1α, which does not 
require processing, is liberated from damaged cells (95). Since IL-1 efficiently activates 
expression of IL-6 in many cell types (96, 97), it is not surprising that these two cytokines are 
found at the sites of local inflammation. The synergistic upregulation of YKL-40 expression by 
IL-1 and IL-6 (or OSM) in in vitro experiments therefore likely recapitulates the regulation of 
YKL-40 in vivo. Similarly to the regulation of YKL-40, IL-1 and IL-6 (or OSM) are known to 
control expression of acute phase proteins in the liver, which are released to the blood to limit  
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inflammation-associated damage and allow for the return to homeostasis. Thus, acute cytokine-
driven expression of YKL-40 is likely highly beneficial and allows for proper resolution of 
inflammation. Nevertheless the mechanism by which YKL-40 limits inflammation remains 
elusive due to limited understanding of YKL-40 receptors and their signaling. In fact YKL-40 
induces the interaction of αvβ3 integrins with syndecan-1 in endothelial cells (82), it activates 
ERK, AKT, and Wnt/β-catenin signaling in macrophages via IL-13 receptor alpha 2-dependent 
mechanism (20), and activates ERK, AKT, and p38 via protease activated receptor 2 in bronchial 
smooth muscle cells (98). It remains to be established whether these proposed 
receptors/mechanisms are important for the biological functions of YKL-40 which are associated 
with inflammation. However, in agreement with the proposed role of YKL-40 in limiting 
inflammation, it has recently been shown that YKL-40 also inhibits NF-κB activation and 
expression of IL-6, IL-8 and MCP-1 by skeletal muscle cells by a protease activated receptor 2-
dependent mechanism (99). 
It is generally accepted that IL-1 triggers a classical NF-κB  pathway in many cell types, 
which leads to the induction of p65/p50 target genes, including those encoding pro-inflammatory 
cytokines such as IL-8 and IL-6 (100). It is also accepted that RelB is activated in lymphoid 
cells, such as dendritic cells, by a non-canonical NF-κB pathway and that generation of RelB/p52 
complexes that are important for proper dendritic cell functions (101). This non-canonical NF-
κB  activation pathway is activated by ligands such as CD40 and lymphotoxin-β (47) but cannot 
be activated by IL-1.  However, it has recently been recognized that in dendritic cells, RelB can 
also  
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be activated by a canonical pathway in response to TNF, LPS and CpG, and this activation 
results in RelB/p50 complex formation (47). This canonical RelB activation depends on TRAF6 
(102) , which is further supported by findings that the RelB/p50 complexes are bound to 
IκBα and IκBε in the cytoplasm (47). It has been also suggested that canonical activation of 
RelB in dendritic cells is possible because of a higher level of RelB expression in these cells and 
the constitutive activation of non-canonical pathway (47). The physiological importance of the 
RelB/p50 complexes is strongly supported by a more deleterious phenotype of RelB-deficient 
than the NIK-deficient mice (103), suggesting that RelB has NIK-independent functions that 
likely can be attributed to RelB/p50 complexes. Nevertheless, the mechanism of specific 
RelB/p50-dependent gene regulation is not clear since RelB/p50 and p65/p50 complexes bind the 
same regulatory sequences. 
Although existence of RelB/p50 complexes in non-lymphoid tissues has been shown 
more than a decade ago (87), the function of these complexes remained elusive. Our data clearly 
demonstrate that RelB expression is strongly induced during sterile inflammation in vivo, and 
this induction is likely mediated by IL-1. IL-1 also strongly activates expression of RelB in 
astrocytes in vitro. RelB subsequently forms complexes with p50 and activation of these 
complexes is controlled by IκBα. Once the RelB/p50 complexes are activated, they regulate 
expression of YKL-40 and likely other RelB/p50-responsive genes. Thus, it appears that 
RelB/p50 complexes may play critical role(s) during sterile inflammation that normally leads to  
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a return to homeostasis. However, chronic inflammation may also lead to pathological 
RelB/p50-dependent gene expression. Indeed, YKL-40 has recently been proposed as a marker 
of a particularly aggressive mesenchymal subtype of GBM (104). In agreement with our current 
findings indicating that RelB regulates YKL-40 expression, RelB is strongly expressed in 
mesenchymal subtype of GBM and promotes expression of mesenchymal genes, including YKL-
40 (104). Furthermore, loss of RelB expression attenuates GBM cell survival, motility and 
invasion (105). 
Our previous and current data suggest that the robust activation of YKL-40 expression 
requires both STAT3 and RelB/p50 binding to the YKL-40 promoter. Surprisingly, OSM also 
promoted formation of the RelB/p50 complexes by the mechanism which currently remains 
unclear but these complexes do not contain STAT3 (data not shown).  
In summary, we propose that sterile inflammation leads to the expression of YKL-40, 
which is induced by IL-1 and cytokines of the IL-6 family. Mechanistically, both STAT3 and the 
RelB/p50 complexes drive the expression of YKL-40 via the elements within the YKL-40 
promoter. 
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Figure 18 Proposed model of regulation of YKL-40 expression in astrocytes during sterile 
inflammation. During sterile inflammation, there is an up-regulation of inflammatory cytokines 
as well as an up-regulation of YKL-40 expression. We propose that IL-1 and OSM, a IL-6 family 
cytokine, can up-regulate YKL-40 expression in astrocytes. This up-regulation is mediated by 
the NF-κB and the JAK-STAT pathway. IL-1 leads to an up-regulation of expression of RelB, 
and p50. Concurrently, OSM activates the JAK-STAT pathway leading to the phosphorylation of 
STAT3. In addition, OSM enhances the binding of RelB to and p50 and this RelB/p50 
heterodimer and STAT3 homodimer translocate to the nucleus and bind to the YKL-40 
promoter, enhancing gene expression. 
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Chapter 4: 
Role of YKL-40 in glioblastoma in vivo 
4.1 Abstract  
Glioblastoma multiforme (GBM) is the most common type of primary brain tumor, with a 5-year 
survival rate of less than 3%. A unique clinical problem in treating GBM is the extensive 
invasiveness of GBM cells. Due to the invasive phenotype and diffuse penetration of GBM into 
normal regions of the brain, standard treatments such as surgery and radiotherapy are ineffective, 
resulting in high rate of relapse and mortality. The high rate of tumor relapse points towards the 
need for more targeted therapeutic approaches. Recently, we reported that YKL-40 is secreted by 
primary human astrocytes and its levels are highly up-regulated in GBM cells (25). Although 
YKL-40 increases migration, invasion, growth, and survival of GBM cells in vitro (25, 106), the 
effect of YKL-40 in vivo on glioma tumor growth and invasion in the brain has not been 
established. We generated human glioma cells expressing inducible shRNA to YKL-40 to 
examine the role of GBM tumors in vivo.  Tumor growth and invasion was analyzed after the 
down regulation of YKL-40 in the tumors grown intracranially. Our results show that although 
YKL-40 regulates invasion in vitro, does not alter tumor growth and invasion in vivo.  
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4.2 Introduction 
Glioblastoma is the most common primary brain tumor in adults with a short survival period. 
The median survival time of glioblastoma patients is approximately 12 months, despite various 
treatments including surgery and radiotherapy. Even after surgical removal of the tumor, there is 
a high relapse and recurrence of the tumor. This is due to highly infiltrative nature of the tumor. 
In fact, invasion is the main cause for treatment failure. Some of the invasive cells that infiltrate 
the area surrounding the tumor can proliferate even after surgical removal of the bulk tumor 
causing relapse. 
Rho family GTPases mediate key signaling elements that module GBM cell invasion. These 
GTPases regulate cell morphology as well as actin dynamics to stimulate cell squeezing through 
the narrow extracellular spaces that are typical of the brain parenchyma (107). The invasion 
phenomenon also depends on the activation or inhibition of proteinases and their inhibitors. 
These processes include two main proteolytic systems: the plasminogen activator system (PAS), 
which controls the activation of the proteinase plasmin from inactive plasminogen, and the 
matrix metalloproteinase (MMPs) and their inhibitors. The ECM of the brain parenchyma is 
modified by the GBM cells to facilitate migration and invasion. MMPs (especially MMP-2, 
MMP-9 and MT1-MMP) are overexpressed in GBM patients, which facilitate invasion by 
cleaving ECM components. Concordantly, down-regulation of MMP-9 decreases in vivo 
invasion and cell motility (28).  
YKL-40 is a member of glycosyl hydrolase family 18, which can bind to chitin but lacks  
 
 
 
 
83 
 
 
catalytic activity. It has been shown to be a marker of chronic inflammation and oncogenic 
transformation (64). It promotes adhesion and migration of vascular smooth muscle cells, and 
acts as chemotactic agent for HUVECs. YKL-40 is highly up-regulated in various cancers 
including breast, colorectal, ovarian, prostate, lung and glioblastoma (12, 16, 108-111). In GBM 
patients, YKL-40 levels positively correlate with higher tumor grade, high relapse and poor 
survival (12, 112-115). In addition, YKL-40 was identified as one of the most overexpressed 
genes in glioblastoma (12, 17, 116-118). Overexpression of YKL-40 in transformed astrocytes 
leads to expression of genes conferring radiation resistance and increased invasion. Furthermore, 
GBM cells show enhanced migration and invasion in response to elevated YKL-40 in vitro (25). 
YKL-40 also induces VEGF expression in GBM cell lines, promoting angiogenesis and 
radioresistance of GBM tumors (82). Administration of YKL-40 antibodies have been shown to 
block growth, angiogenesis, and progression of xenografted tumors in flanks of mice (119) 
Inflammation is associated with cancer incidence and actively promotes tumor progression (120). 
The expression of pro-inflammatory cytokines including IL-1, IL-6, OSM, and TNFα as well as 
prostaglandins are highly up-regulated in cancer cells as well as cancer associated inflammatory 
cells (121-123). In addition, GBMs have higher expression levels of IL-6 and OSM leading to 
constant activation of STAT3 signaling (124). GBM have also been have shown to secrete 
substantial amounts of IL-1, which results in the secretion of other cytokines, such as IL-6 and 
IL-8, and promotes GBM proliferation. We have recently shown that YKL-40 expression is up-
regulated by IL-1 and OSM during sterile inflammation. 
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Collectively, these observations suggest that YKL-40 is a key mediator in GBM progression. 
However, the in vivo function of YKL-40 in GBM is not well understood. In this study, we 
evaluate the role of YKL-40 in an invasive GBM model in vivo. We found that YKL-40 
expression is up-regulated in the presence of IL-1 and OSM in GBM cells. 
As reported before, YKL-40 effects the invasion and migration of GBM cells in vitro; however it 
does not affect tumor growth or invasion in vivo.  
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4.3 Results 
4.3.1. Gene expression profile of U1242 glioma cells: Invasiveness is a characteristic 
phenotype of human glioma, which is rarely seen in human xenografts established from tissue 
culture cell line, and is propagated as orthotropic tumor in mice. The U1242 glioma cell line is 
unique as it has invasive and aggressive phenotypes when grown in nude mice (28). We here 
characterized the expression profile of these cells as compared to U373, a non-invasive  glioma 
cells commonly used and primary human astrocytes. We observed that U1242 cells express 
lower levels of GLAST (Glutamate Aspartate transporter), NESTIN, GFAP and CD44 but 
comparable levels of YKL-40 mRNA as compared to U373 glioma cells. 
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Figure 19 Gene expression profile of U1242 cells. RNA was isolated from U1242, U373 cells 
and astrocytes. Taqman qPCR was performed for NESTIN, CD44, YKL-40, GFAP and GLAST 
mRNA was normalized to expression of GAPDH.  
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4.3.2. YKL-40 controls migration and invasion of U1242 glioma cells in vitro. High 
expression of YKL-40 is associated  with invasive GBM tumors (114). We have previously 
shown that YKL-40 promotes the migration of astrocytes and in vitro invasion of U373 glioma 
cells which are not invasive in vivo. We evaluated whether YKL-40 also regulates in vitro 
migration and invasion of U1242 glioma cells. The migration of U1242 cells was reduced by 
50% when YKL-40 was downregulated (Fig 20A). Conversely, migration of U1242 cells was  
markedly increased in response to exogenous YKL-40 (Fig 20B). Similarly, invasion of U1242 
cell was decreased by down-regulation of YKL-40  expression (Fig 21A) and increased in 
response to exogenous YKL-40 (Fig 21B).  
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Figure 20 YKL-40 controls glioma cell migration in vitro. (A) Transwell migration assay was 
done in U1242 cells transfected with si-Ctr, or si-YKL-40 30 hours post transfection.(B) U1242 
cells were stimulated with YKL-40 (200 ng/ml) for 8hrs. Transwell migration assay was done 
on fibronectin coated membrane 
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Figure 21 YKL-40 controls glioma cell invasion. Matrigel invasion assay was done with 
U1242 cells in Boyden chamber with cells transfected with siCtr or si-YKL-40 (A) or after 
stimulation of U1242 cells with YKL-40 (200 ngm/ml). (B) Cells were allowed to invade 
through the matrigel for 8 hrs. Cells that invaded into the matrigel were counted from six 
random fields per experiments (represented as cells invaded per field). 
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4.3.3. The expression of YKL-40 is induced by IL-1 and OSM. GBM associated 
inflammation, like most cancer associated inflammation leads to an up-regulation of pro-
inflammatory cytokine expressed both in infiltrating immune cells as well as resident tumor cells. 
YKL-40 expression has been shown to increase in response to IL-1 and OSM, a IL-6 family 
cytokine. To this end, we stimulated U1242 cells with IL-1 and OSM. Expression of YKL-40 
mRNA was activated 14 fold in the presence of IL-1 and OSM (Fig 22A). Furthermore, we 
analyzed the migration and invasion of U1242 cells in the presence of IL-1 and OSM. We found 
that IL-1 and OSM enhance the migration and invasion of U1242 cells (Fig 22B,C).  
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Figure 22 IL-1 and OSM enhance YKL-40 expression, migration and invasion of 
U1242 cells. U1242 cells were stimulated with IL-1 and OSM for 20 hrs, followed by 
analysis of YKL-40 mRNA expression by qPCR, normalized to GAPDH (A). Transwell 
migration (B) and invasion (C) was analyzed as described before in the presence of IL-1 
and OSM.  
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4.3.4. Inducible down-regulation of YKL-40 in U1242 cells. We constructed an inducible 
system, where YKL-40 expression could be knocked-down in response to doxycycline in 
U1242 glioma cells. We utilized the TRIPZ vector, which has a Tet-inducible shRNA 
expression (Fig 23). The Tet-inducible promoter is upstream of the shRNA, RFP and 
puromycin resistance genes. Therefore, the induction of this vector by 
doxycycline/tetracycline induces the expression of RFP in these cells, which is shown in 
Fig 24A and Fig 25A. The cells once infected, and then selected by puromycin, were 
assessed for the down-regulation of YKL-40 expression. Unstimulated U1242 produce low 
levels of YKL-40, making assessment of down-regulation rather difficult. Therefore, to 
better visualize the down-regulation of YKL-40, we utilized cytokine stimulated U1242 
cells. Once stimulated U1242 cells showed an enhanced expression of YKL-40 (7.5 fold), 
which was downregulated in the presence of doxycycline (70% downregulation) (Fig 25). 
In addition we analyzed the migration (Fig 26) and invasion (Fig 27) of the U1242 shCtr 
(U1242 with scrambled shRNA) and U1242 shYKL-40 (U1242 with shRNA to YKL-40) 
cells after induction by IL-1 and OSM, followed by down-regulation of YKL-40 expression 
by doxycycline. We observed a decrease in migration and invasion of U1242shYKL-40 
cells in response to YKL-40 down-regulation.  
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Figure 23 Generation of U1242 cells with inducible knock down of YKL-40. (Top) 
Experimental design to construct an inducible knockdown of YKL-40 is shown above. The 
U1242 cells were first infected with lentivirus to produce U1242 cells expressing inducible 
shCtr and shYKL-40. This was followed by infection of U12424 shCtr and U1242 shYKL-
40 with lentivirus containing GFP and luciferase describe materials and methods. (Bottom) 
Schematic representation of TRIPZ lentivirus vector utilized to create stable cells with 
inducible knockdown of YKL-40. 
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Figure 24 Induction of RFP U1242 shCtr and U1242shYKL-40 cells. (A) A schematic 
diagram showing the position of RFP, shRNA and puromycin resistance gene down stream 
of tetracycline inducible promoter in the TRIPZ vector. (B) The cells were plated, treated 
with doxycycline (1µg/ml) for 48 hours, and RFP expression was visualized using 
microscope.  
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Figure 25 Knock-down of YKL-40 in U1242 stable cells. U1242GL shCtr and U1242 shYKL-
40 cells were treated with doxycycline (1µg/ml) for 50 hours, with intermittent treatment with 
IL-1 and OSM after 30 hours for a time period of 20 hours. YKL-40 mRNA expression was 
analyzed by qPCR. 
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Figure 26 Down-regulation of YKL-40 decreases the migration of U1242 stable cells. U1242 
shCtr and U1242shYKL-40 cells were treated with doxycycline for 50 hours, with intermittent 
treatment with IL-1 and OSM after 30 hours for a time period of 20 hours. Migration of these 
cells was analyzed using Boyden chamber as described in materials and methods. 
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Figure 27 Down-regulation of YKL-40 decreases the invasion of U1242 stable cells. U1242 
shCtr and U1242 shYKL-40 cells were induced with doxycycline for 50 hours, with intermittent 
treatment with IL-1 and OSM after 30 hours for a time period of 20 hours. Invasion of these cells 
was analyzed using Boyden chamber as described in materials and methods. 
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4.3.5 GFP expression in U1242GL shCtr and shYKL-40. In order to perform in vivo 
experiments using U1242GL cells, we sorted U1242GL shCtr and U1242shYKL-40 to obtain 
cell populations with similar GFP and luciferase expression. First, cells were FACS sorted for the 
expression of GFP (Fig 28A) and populations expressing similar levels of GFP were used for 
further experiments. Subsequently, U1242GL shCtr (Fig 28A) and U1242GL shYKL-40 
(Fig28B) cells were analyzed for the expression of luciferase. Indeed, these cells expressed 
similar levels of luciferase (Fig 28C).  
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Figure 28 GFP and Luciferase expression in U1242GL shCtr and U1242GL shYKL-40 
cells. The two cell types were analyzed using FACS. The population of cells expressing high and 
similar amount of GFP were isolated and utilized for further experimentation. U1242GL shCtr 
(A) and U1242GL shYKL-40 (B). Additionally, these isolated population of cells were then 
analyzed using the luciferase assay. Equal number of cells were plated overnight and were lysed 
using lysis buffer. Substrate with equal protein concentration was utilized for luciferase assay. 
Luciferase activity was then calculated (C). 
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Figure 29 In vivo experimental design. To assess the in vivo effects of YKL-40, we performed 
a tumor xenograft study. Athymic female mice were implanted with U1242GL shCtr and 
U1242GL shYKL-40 cells. The tumor was imaged using a Caliper IVIS-200 at 7, 14, 21, 28 days 
of tumor implantation. Half the mice from each group (n=7) were fed a doxycycline diet to 
induce the expression of shRNA control and YKL-40. 
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4.3.6. YKL-40 does not affect tumor growth in vivo. To assess whether tumor derived YKL-40 
regulates glioma tumor growth in vivo, we implanted U1242GL shCtr and U1242GL shYKL-40 
cells in brains of nude mice as described in materials and methods. Tumors were allowed to 
grow for 7 days and then mice were fed either normal or doxycycline diet to induce shRNA 
expression. Tumor growth was monitored by measuring luminescence. We found that there was 
no significant difference in tumor growth between the four groups, suggesting thatYKL-40 does 
not influence tumor growth. 
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Figure 30 In vivo tumor growth after knock-down of YKL-40 expression. The mice, were 
imaged at day 7, 14, 21, 28 post tumor implantation using a Caliper-IVIS 200. Representative 
images are shown in (B). The calculated bioluminescence was used to calculate tumor growth for 
4 groups of animals bear tumors containing, U1242GL shCtr without doxycycline (shctr), 
U1242GL shCtr with doxycycline (shctr Doxc), U1242GL shYKL-40 without doxycycline 
(shYKL) and U1242GL with doxycycline (shYKL Doxc) 
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4.3.7. Down-regulation of YKL-40 in U1242GL cells does not affect their invasion in vivo. 
We utilized the tumor xenograft model and immunohistochemistry to analyzed the effect of  
down-regulation ofYKL-40 in GBM cells in vivo. 30 days post-tumor implantation, whole 
animal perfusion, followed by OCT embedding of brain was performed as described in materials 
and methods. Tumors from the four groups U1242GL shCtr without doxycycline (shctr), 
U1242GL shCtr with doxycycline (shctr Doxc), U1242GL shYKL-40 without doxycycline 
(shYKL) and U1242GL with doxycycline (shYKL Doxc) were sectioned and stained for Hoechst 
and anti-RFP. Representative images of 10µm sections, stained with Hoechst (nucleus) and anti-
RFP (doxycycline induction), followed by tiled whole brain imaging using Ariol microscope are 
shown in Fig 31A. These images were analyzed for tumor invasion using Image pro4.5 software. 
The average of 7 points per tumor for 7 different tumors from each group were utilized to assess 
tumor invasion. The average distance of the center of the tumor to the farthest points within the 
four groups is depicted in Fig 31B. No significant difference in tumor invasion was observed 
within the four groups. 
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Figure 31 Invasion of U1242GL cells after YKL-40 knock-down. (A) 10µm sections were 
stained for Hoechst (nucleus) and anti-RFP. (Top left) Hoechst stained whole brain slice. (Top 
right) GFP expression in the U1242GL tumor cells growing as an invasive tumor in the mouse 
brain. (Bottom) in the RFP expression in the tumor cells after induction by doxycycline. (B) 
Maximal Distance of invasion of four groups of U1242GL tumor cells: U1242GL shCtr without 
doxycycline (shctr), U1242GL shCtr with doxycycline (shctr Doxc), U1242GL shYKL-40 
without doxycycline (shYKL) and U1242GL with doxycycline (shYKL Doxc), in the mouse 
brain 30 days post implantation was analyzed.  
 
 
 
 
 
 
 
 
4.4 Discussion: 
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In the past, the standard of care for glioblastoma has been surgical resection, radiation therapy, 
and a frontline chemotherapeutic, such as temozolomide. Despite aggressive intervention, GBM 
patients have a poor survival rate with near universal relapse after surgical removal and 
chemotherapy. This high rate of relapse is attributed to the infiltrative nature of the GBM cells, 
which invade the brain, escape surgical removal, and resurface as a new tumor shortly thereafter.  
YKL-40 is a secreted glycoprotein which is up-regulated in GBM (12, 106). Additionally YKL-
40 plays a role in glioblastoma pathology as it has been shown to mediate angiogenesis, and 
radioresistance (82). Not surprisingly YKL-40 levels have been shown to be highly correlated 
with tumor grade, and alarmingly, YKL-40 is one of the most overexpressed genes in GBM 
when compared to low grade glioma and normal brain via competitive hybridization array (12, 
125). Despite this, the exact role of YKL-40 at the site of tumor infiltration remains to be 
established. YKL-40 has been shown to promote invasion in transformed glial cells in vitro. 
However, most cell lines used in in vitro settings to study invasion form encapsulated tumors in 
vivo when used in xenograft models, leading to poor recapitulation of the human disease. To 
address this, we utilized U1242 cells which spread invasively in the brain with a high mitotic 
index in xenograft models, in an effort to mimic human disease. We generated U1242 cells  
 
 
 
stably expressing shRNA to YKL-40 upon doxycycline induction after tumor implantation. We 
observed that there was no change in tumor growth in these mice as compared to control mice. In  
all three experimental conditions, we also observed no difference in the invasive capacity of the 
glioma cells. YKL-40 is a protein that has been shown to be elevated during inflammatory 
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conditions or pathologies associated with inflammation. We did not observe a decrease in 
invasive capacity in glioma cells down-regulating YKL-40, however the model that we used 
does present some shortcomings. One such drawback is the lack of an immune component of the 
athymic nude mice, which may prevent adequate recapitulation of the effects of YKL-40 seen in 
real pathologic inflammatory microenvironments due to cross talk between YKL-40 and the 
immune system. Furthermore our doxycycline induction occurred seven days after tumor 
implantation, and thus recapitulates the effects of YKL-40 on invasive capacity of tumor that has 
already substantially grown. Additionally, knocked down YKL-40 expression in glioma cells 
does not account for the effects of YKL-40 secreted by other cells in the brain. All of these 
factors may influence the data that we obtained and could have prevented us from observing 
YKL-40 function with respect to invasive capacity. Therefore, although our data suggest that 
YKL-40 does not affect invasion of tumors implanted in nude mice, it is possible that it promote 
the invasion of GBM cells in humans. 
 
 
 
 
 
5. General Discussion: 
RelB a member of the NF-κB family, has been shown to regulate dendritic cell maturation, and 
differentiation as well as development of endotoxin tolerance. Recently, it has been shown to be 
an oncogenic driver of mesenchymal glioma growth (105). In this study, we demonstrate that 
RelB expression is up-regulated in sterile inflammation in vivo. RelB expression is increased in 
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response to IL-1 both in primary human and mouse astrocytes as well as  glioma cells. IL-1 
induces RelB expression, which binds to p50, and RelB/p50 heterodimer then translocates to the 
nucleus and binds the YKL-40 promoter to enhance YKL-40 expression. YKL-40 has been 
shown to be up-regulated in variety of inflammatory diseases. 
Our data raise several questions that still remain unanswered : 
1. Why is IL-1 induction of YKL-40 expression controlled by RelB and not p65 ?  
2. What up-regulates RelB expression in response to IL-1? 
3. What could be the effect of YKL-40 on recruitment of other cells such as neural progenitors 
at the site of GBM as well as survival of glioma stem cells. 
Pro-inflammatory vs Anti-inflammatory response: Why is IL-1 induction of YKL-40 
expression controlled by RelB and not p65 ? 
Studies in RelB knockout mice have shown that RelB is important in the development of 
medullary epithelium, mature dendritic cell function, secondary lymphoid tissue organization,  
 
 
 
 
 
 
and thymic negative selection (126, 127). These mice exhibit pre-mature mortality due to, 
multi-organ inflammation. Although the immune system lesions observed in RelB-deficient 
mice are consistent with the established role of NF-κB regulation of in hematopoietic tissues, 
the role of RelB in the inflammatory process remains obscure. We hypothesize that YKL-40 
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expression in inflammation is controlled by RelB and not p65 due to the role of RelB in 
resolution of inflammation. 
RelB has been reported to possess potent anti-inflammatory properties (128-130). Targeted 
overexpression of RelB ablates cigarette smoke induced inflammation in mice in vivo (128). 
Elevated RelB expression has been correlated with the repression of pro-inflammatory gene 
expression (131). Furthermore, RelB has been shown to bind and sequester p65, which inhibits 
the binding of p65 to its promoter, hence inhibiting the expression of pro-inflammatory genes in 
LPS (Lipopolysaccharide) tolerant cells. LPS can induce RelB expression, which activates a 
negative feedback loop to balance the immune response.  
In our study, we show that YKL-40 expression is modulated by RelB in response to IL-1 and 
OSM. YKL-40 is marker of chronic inflammation and is up-regulated in various inflammatory 
conditions but its role in inflammatory conditions is not well understood. YKL-40 knockout 
mice show an exacerbated response to EAE as well as an enhanced inflammatory response to 
hyperoxia (71, 72) Interestingly, YKL-40 knockout mice showed impaired allergen (OVA) 
sensitization as well as similar inflammation in response to cigarettes as compared to wild types  
 
 
 
 
(14, 132). Taken together, these studies insinuate that YKL-40 dependent regulation of 
inﬂammation may vary depending on the speciﬁc type of immune activation, and cell signaling, 
as well as the tissue involved. In the case of astrocytes, which are an important modulators of 
neuroinflammation, we show that up-regulation in YKL-40 expression is dependent on RelB 
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regarded as an anti-inflammatory member of the NF-κB family rather than p65, which is known 
to mediate pro-inflammatory gene expression. We hypothesize, that this alternate pathway of 
RelB instead of p65 to modulate YKL-40 gene expression highlights the potential role of YKL-
40 to curb excessive inflammation to restore a balance during neuroinflammation. We speculate 
that YKL-40 expression in astrocytes is up-regulated in response to IL-1 via RelB to curb the 
overwhelming inflammatory response, via prevention of immune cell infiltration and activation 
of gliosis to prevent damage to the brain in case of excessive inflammation.  
What up-regulates RelB expression in response to IL-1? 
RelB promoter has two κB binding sites and RelB expression is modulated by RelA in 
monocytes (133). Once RelB is initially transcribed in a RelA dependent manner, it is then 
constitutively autoregulated in a transcriptionally dependent manner (133). In BMDC (bone 
marrow derived dendritic cells) its expression can be modulated by cRel (47). In our study, 
down regulation of p65, and cRel has no effect on cytokine mediated expression of YKL-40. 
We observed a 25 fold up-regulation in RelB gene expression when astrocytes were stimulated  
with IL-1. This up-regulation is not completely diminished by down-regulation of p65 or cRel  
 
 
 
 
in these cells (data not shown). Taken together these studies indicate that RelB expression in 
astrocytes in response to IL-1 might initially be p65 dependent followed by auto-regulation by 
RelB. 
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What could be the effect of YKL-40 on recruitment of other cells such as neural 
progenitors ? 
YKL-40 is a glycoprotein that is secreted and can have both auto as well as paracrine functions 
(19, 67). YKL-40 enhances the migration of astrocytes, GBM cells, and glioma stem cell (data 
not shown) (25, 106). In our study, we evaluated the effect of down regulation of YKL-40 
secreted by GBM cells. In the future, the role of YKL-40 secreted by surrounding cells in the 
brain still needs to evaluated. Neural stem cells are cells in the brain that show enhanced 
migratory capacity and have long been studied , to understand their role in GBM and potentially 
utilize them as targets to develop better therapeutics. Neural stem cell tropic studies in GBM, 
indicates that NSC migration can be extensive, even in the adult brain and along 
nonstereotypical routes, in GBM (134). GBM like other cancers, is accompanied by 
inflammation and up-regulation of cytokines like IL-1, IL-6 and OSM. We observed, an up-
regulation of YKL-40 expression in NSC in response to IL-1 and OSM. The role of these NSC 
on glioma progression needs to evaluated. In addition, the potential role of YKL-40 in attracting 
NSCs to glioma site, still needs to be explored. 
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